Pfizer Receives European Commission Approval for Lorbrena as First-Line ALK-Positive NSCLC Treatment

Pfizer today announced that the European Commission has approved Lorbrena (lorlatinib) as first-line treatment for adults with ALK-positive non-small cell lung cancer (NSCLC) in the European Union. The approval was based on results from the Phase 3 CROWN trial, which demonstrated superior progression-free survival compared to crizotinib. This approval makes Lorbrena available as a first-line treatment option for ALK-positive NSCLC patients across all EU member states. Pfizer is committed to ensuring broad patient access to Lorbrena in Europe.